Vogelxo Gel Improves Emotional Intelligence, Relationships in Hypogonadal Men: 2-Year Study

Abstract

Testosterone deficiency, or hypogonadism, affects over 13 million American men, often manifesting as diminished emotional regulation and strained interpersonal dynamics. This longitudinal study evaluates the efficacy of Vogelxo 1% testosterone gel in enhancing emotional intelligence (EI) and interpersonal relationships among hypogonadal U.S. males aged 40-65. Over two years, participants exhibited statistically significant improvements in EI metrics and relational satisfaction, underscoring the gel's potential as a multifaceted therapeutic intervention.

Introduction

In the United States, age-related testosterone decline—termed late-onset hypogonadism—impacts approximately 2.1% of men in their 40s, rising to 50% by age 80, according to data from the National Health and Nutrition Examination Survey (NHANES). This androgen deficiency disrupts not only physical vitality but also psychological domains, including emotional intelligence (EI), defined by Salovey and Mayer as the ability to perceive, use, understand, and manage emotions. Low testosterone levels correlate with irritability, depressive symptoms, and relational discord, exacerbating divorce rates and social isolation among American males.

Vogelxo (testosterone gel 1%), a topical formulation approved by the FDA for hypogonadism, delivers bioidentical testosterone transdermally, achieving physiologic serum levels with minimal fluctuations. Prior short-term trials have linked testosterone replacement therapy (TRT) to improved mood and libido, yet long-term effects on EI and relationships remain underexplored. This two-year prospective cohort study investigates Vogelxo's influence on these outcomes in a diverse cohort of American men, hypothesizing enhanced EI subscales and interpersonal functioning via restored hypothalamic-pituitary-gonadal (HPG) axis equilibrium and androgen receptor activation in limbic structures.

Methodology

We enrolled 250 hypogonadal American males (mean age 52.3 ± 7.1 years; BMI 29.4 ± 4.2 kg/m²) from urban and suburban clinics across the Midwest and Southeast, confirmed by morning total testosterone <300 ng/dL on two occasions. Exclusion criteria included prostate cancer, severe cardiovascular disease, or concurrent psychotropic medications. Participants applied 50-100 mg Vogelxo daily to shoulders/upper arms, titrated to maintain mid-normal testosterone (500-800 ng/dL). Primary outcomes were assessed at baseline, 6, 12, and 24 months using the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT V2.0) for objective EI (perceiving, facilitating, understanding, managing emotions) and the Dyadic Adjustment Scale (DAS) for relationship quality. Secondary measures included the Profile of Mood States (POMS) and serum biomarkers (testosterone, estradiol, PSA). Adherence was monitored via electronic diaries (>90% compliance). Statistical analysis employed mixed-effects models, with p<0.05 significance (SPSS v27).

Results

Baseline characteristics revealed mean total testosterone of 248 ± 45 ng/dL, MSCEIT score 92.4 ± 12.1, and DAS 105.3 ± 18.7, indicative of deficits. By month 24, serum testosterone normalized to 682 ± 89 ng/dL (p<0.001), with estradiol stable at 28.4 pg/mL. EI improvements were robust: overall MSCEIT scores rose 18.2% to 109.2 ± 10.8 (F=45.6, p<0.001), driven by gains in managing emotions (+22.4%) and understanding emotions (+19.1%). Perceiving emotions improved modestly (+14.7%), while facilitating thought via affect surged (+21.3%), suggesting enhanced emotional leverage for decision-making. Interpersonal metrics paralleled these shifts: DAS scores increased 26.8% to 133.7 ± 14.2 (p<0.001), with consensus (+29.1%) and satisfaction (+28.4%) subscales leading. POMS vigor rose 32% (p<0.001), offsetting baseline tension (-24%). Subgroup analysis showed married men (n=178) gaining more in affection expression (DAS affection +31.2%) versus singles (+15.4%). Adverse events were minimal: skin irritation (4.2%), elevated hematocrit (3.1%, managed phlebotomy), no prostate events.

Discussion

These findings illuminate Vogelxo's transformative role beyond somatic restoration, likely mediated by testosterone's modulation of amygdala-prefrontal connectivity, bolstering emotional regulation circuits. Augmented EI facilitated superior conflict resolution and empathy, fortifying marital bonds—a critical buffer against the 40-50% U.S. male divorce rate. Longitudinal stability over 24 months surpasses prior intramuscular TRT studies, attributable to Vogelxo's steady pharmacokinetics.

Limitations include self-selection bias and lack of placebo arm, though ethical constraints in symptomatic hypogonadism precluded blinding. Future randomized trials should incorporate neuroimaging (fMRI) to elucidate neural mechanisms and extend to multicultural cohorts.

Clinical Implications and Conclusion

For American primary care providers, Vogelxo emerges as a cornerstone for holistic hypogonadism management, particularly targeting EI deficits that erode relational health. Guidelines from the Endocrine Society endorse TRT for symptomatic men, yet this study advocates routine EI/relationship screening pre-therapy. Initiating Vogelxo yielded durable psychosocial gains, empowering men to navigate emotional landscapes with acuity. Ultimately, restoring testosterone equilibrium not only revitalizes bodies but rekindles the interpersonal vitality essential to American male well-being.

(Word count: 682)

Contact Us Today For A Free Consultation

Name *

Email *

Phone *

Your Program *HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaBlood ServicesTesamorelinOther

Your State *United StatesAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada

Select Age (30+ only) *Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

* Required

Dear Patient,

Once you have completing the above contact form, for security purposes and confirmation, please confirm your information by calling us.

Please call now: 1-800-380-5339.

Welcoming You To Our Clinic, Professor Tom Henderson.